Geoffrey Alilonu, MD
Nephrology · Northport, ALNPI 1144295221
Payments from drug & device makers
Across 574 payments — averaging $14.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$2K
- AstraZeneca$1K
- Fresenius USA Marketing, Inc.$1K
- Amgen$973
- Akebia Therapeutics Inc$751
- Vifor Pharma, Inc.$519
- plus $2K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 220 | $1,515 |
| AstraZeneca(2 entities) | 62 | $1,164 |
| Fresenius USA Marketing, Inc. | 75 | $1,083 |
| Amgen(2 entities) | 45 | $973 |
| Akebia Therapeutics Inc | 32 | $751 |
| Vifor Pharma, Inc. | 31 | $519 |
| Otsuka America Pharmaceutical, Inc. | 22 | $436 |
| Travere Therapeutics, Inc. | 13 | $265 |
| GSK | 11 | $196 |
| Bayer | 10 | $172 |
| Novo Nordisk | 12 | $158 |
| Daiichi Sankyo Inc. | 7 | $151 |
| Calliditas Therapeutics US Inc. | 6 | $138 |
| Bard Peripheral Vascular, Inc. | 2 | $120 |
| Novartis | 4 | $100 |
| Renalytix AI, Inc. | 1 | $92 |
| Mallinckrodt Enterprises LLC | 4 | $77 |
| Ardelyx, Inc. | 3 | $70 |
| Aurinia Pharma U.S., Inc. | 3 | $61 |
| Shire North American Group Inc | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 2 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $19 |
| Nxstage Medical, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$8,236 in reported general payments places this provider in the 70th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Northport
- David TietjenHuntsville$2.6M
- Dana RizkBirmingham$2.6M
- Michael QuadriniHuntsville$1.3M
- Eric WallaceBirmingham$1.3M
- David BainsHuntsville$856K
- Michal MrugBirmingham$793K
- Phillip MadoniaAlabaster$475K
- Carlo CastilloHuntsville$461K
- Sumeet MunjalMontgomery$191K
- Gaurav AgarwalBirmingham$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.